Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-09-02
2008-09-02
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S321000, C514S414000, C514S415000, C514S422000, C514S452000, C514S454000, C546S198000, C546S281100, C546S284100, C548S454000, C548S950000, C549S058000, C549S359000, C549S471000
Reexamination Certificate
active
11513700
ABSTRACT:
Compounds of the Formula:are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
REFERENCES:
patent: 6458802 (2002-10-01), Tran et al.
patent: 2002/0183355 (2002-12-01), Tran et al.
patent: 0 559 285 (1993-09-01), None
patent: 0 771 800 (1997-05-01), None
patent: 0 963 983 (1999-12-01), None
patent: 94/02477 (1994-02-01), None
patent: 94/24125 (1994-10-01), None
patent: 00/38677 (2000-07-01), None
patent: 02/072587 (2002-09-01), None
patent: 02/085911 (2002-10-01), None
Artigas, F., et al., “Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors,”Arch Gen Psychiatry, Mar. 1994, 51, 248-251.
Birch, A. M. et al., “N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D2Antagonists/5-HT1APartial Agonists with Potential as Atypical Antipsychotic Agents,”J Med Chem, 1999, 42, 3342-3355.
Blier, P., et al., “Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression,”J. of Clinical Psychopharmacology, 1995, 15(3), 217-222.
Bundgaard, H., “Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs,”Advanced Drug Deliver Reviews, 1992, 8, 1-38.
Cheetham, S.C., et al., “[3H]paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments,”Neuropharmacol., 1993, 32(8), 737-743.
Hall, M.D., et al., “{3H] 8-hydroxy-2-(Di-n-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain,”J. Neurochem., 1985, 44, 1685-1696.
Lazareno, S., et al., “Pharmacological characterization of acetylcholine-stimulated [3S]-GTPγS binding mediated by human muscarinic m1-m4 receptors: antagonist studies,”Br. J. Pharmacol., 1993, 109, 1120-1127.
Ostrowski, S., “A synthesis of fused pyrimidine mono-n-oxides,” Heterocycles, 1996, 43(2), p. 389-396.
Patani and LaVoie, “Bioisosterism: A Rational Approach in Drug Design,”Chem. Rev., 1996, 3147-3176.
Perez, V., et al., “Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment,”The Lancet,m May 31, 1997, 349, 1594-1597.
Tome, M.B., et al., “Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency,”Int. Clin. Psychopharmacol., 1997, 12, 81-89.
Tome, M.B., et al., “Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and respons to paroxetine and pindolol,”J. Affect Disord., 1997, 44, 101-109.
Wilen, S.H., “Tables of Resolving Agents and Optical Resolutions,”Univ. of Notre Dame Press, Notre Dame, IN, E.L. Eliel (Ed.), 1972, p. 268-298.
Wilen, S.H., et al., “Strategies in optical resolutions,”Tetrahedron, 1977, 33, 2725-2736.
Bundgaard, H. (ed.),Design of Prodrugs, Elsevier (1985), Ch. 1 (pp. 1-92), Ch. 4 (pp. 157-176), Ch. 5 (pp. 177-198), and Ch. 6 (pp. 199-241).
Bundgaard, H. et al., “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties,”J. of Pharmaceutical Sciences, Apr. 1988, 77(4), 285-298.
Eliel, E. L.,Stereochemistry of Carbon Compounds, McGraw Hill, NY (1962) Ch. 4, pp. 46-87.
Higuchi and Stella (eds.),Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975), pp. 1-115 and 196-223.
Jacques, J. et al.,Enantiomers, Racemates and Resolutions, Wiley Interscience, NY (1981) pp. 251-434.
Krogsgaard-Larsen et al., (ed).Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-123, 1991.
Remington's Pharmaceutical Sciences, 17thEd., Gennaro, A. R. (Ed.), Mack Publishing Company, Easton, PA (1985) pp. 1409-1677.
Widder, et al. (ed.),Methods in Enzymology, vol. 112, Academic Press (1985), pp. 309-323.
Stack Gary Paul
Zhou Dahui
Kosack Joseph R
Shiao Rei-tsang
Woodcock & Washburn LLP
Wyeth
LandOfFree
Antidepressant azaheterocyclylmethyl derivatives of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antidepressant azaheterocyclylmethyl derivatives of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antidepressant azaheterocyclylmethyl derivatives of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3917755